Financial Overview: As of September 30, 2025, Abivax reported cash and cash equivalents of €589.7 million, which is expected to fund operations into Q4 2027, indicating strong financial management amid ongoing clinical trials.
Increased Operating Loss: The operating loss for the nine months ended September 30, 2025, reached €174.4 million, an increase of €44.2 million from the same period in 2024, primarily driven by rising R&D expenses, reflecting the company's commitment to advancing its clinical programs.
Surge in R&D Expenses: R&D costs rose to €133.4 million, up €25.4 million year-over-year, largely due to the progression of clinical trials for ulcerative colitis and Crohn's disease, highlighting the company's aggressive investment in drug development.
Widened Net Loss: The net loss for the nine months ended September 30, 2025, was €254.1 million, an increase of €117.3 million compared to the previous year, primarily impacted by financial losses and significant non-cash expenses, indicating ongoing financial strain on the company.
ABVX
$117.91+Infinity%1D
Analyst Views on ABVX
Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is 129.25 USD with a low forecast of 101.00 USD and a high forecast of 176.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast ABVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABVX is 129.25 USD with a low forecast of 101.00 USD and a high forecast of 176.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 125.545
Low
101.00
Averages
129.25
High
176.00
Current: 125.545
Low
101.00
Averages
129.25
High
176.00
Truist
Gregory Renza
Buy
initiated
$140
2025-11-24
Reason
Truist
Gregory Renza
Price Target
$140
2025-11-24
initiated
Buy
Reason
Truist analyst Gregory Renza initiated coverage of Abivax with a Buy rating and $140 price target. Following a second-half re-rate from phase 3 induction data in ulcerative colitis, investors are focused on obefazimod's increasing value proposition and set-up for key phase 3 UC maintenance data in Q2 of 2026 and phase 2b induction topline in Crohn's disease coming the second half of 2026, the analyst tells investors in a research note. Obefazimod represents an unusual mechanism of action, which the firm views as being backed by preclinical and clinical evidence indicating broad immunological effects, Truist added.
Wolfe Research
Outperform
initiated
$176
2025-11-05
Reason
Wolfe Research
Price Target
$176
2025-11-05
initiated
Outperform
Reason
Wolfe Research initiated coverage of Abivax with an Outperform rating and $176 price target. The company's odds of success in Crohn's disease may be higher than that of ulcerative colitis, the analyst tells investors in a research note. The firm says that with ulcerative colitis already succeeding, and with obefazimod having a better mechanism for Crohn's disease, the Crohn's readout is a better catalyst in 2026.
Citizens JMP
Outperform
maintain
$95 -> $114
2025-09-25
Reason
Citizens JMP
Price Target
$95 -> $114
2025-09-25
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Abivax to $114 from $95 and keeps an Outperform rating on the shares after the company announced that results from the obefazimod Phase 3 induction trials will be presented next month. The firm believes the Phase 3 results can reinforce the strength of obefazimod's efficacy, and increase conviction in its multi-billion dollar sales potential. In anticipation, Citizens increased the drug's peak sales estimates.
Morgan Stanley
NULL -> Overweight
upgrade
$71 -> $101
2025-09-12
Reason
Morgan Stanley
Price Target
$71 -> $101
2025-09-12
upgrade
NULL -> Overweight
Reason
Morgan Stanley raised the firm's price target on Abivax to $101 from $71 and keeps an Overweight rating on the shares. After the company reported first half results and attended the firm's Global Healthcare Conference, the analyst sees higher odds of success for the Crohn's indication for obefazimod following discussions with management.
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
